Mesoblast (MEOBF) Inventory Average (2025 - 2026)
Mesoblast's (MEOBF) quarterly Inventory Average came in at $24.9 million in Q2 2026, up 7.18% year-over-year from $23.2 million in Q2 2025, and up 13.36% quarter-over-quarter from $22.0 million in Q4 2025.
Powered by 
Analysis
Mesoblast (MEOBF) Inventory Average (2025 - 2026) Analysis & Trends
Mesoblast has disclosed Inventory Average across 2 years of filings, most recently posting $24.9 million for Q2 2026.
- In Q2 2026, Inventory Average rose 7.18% year-over-year to $24.9 million; the TTM figure through Jun 2026 stood at $24.9 million (up 7.18% YoY), while the FY2026 annual figure was $25.2 million, changed N/A from the prior year.
- Inventory Average came in at $24.9 million for Q2 2026 at Mesoblast, up from $22.0 million in the prior quarter.
- In the past five years, Inventory Average ranged from a high of $24.9 million in Q2 2026 to a low of $22.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.42 Bn | 112.79 Mn | 44.10 Mn |
| 2 | CRISPR Therapeutics AG | 5.20 Bn | 5.20 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.78 Bn | 3.49 Bn | 55.72 Mn | 56.98 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 39.30 Mn |
| 5 | uniQure | 3.06 Bn | 3.06 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.68 Bn | 2.68 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 17.49 Mn |
| 8 | Sarepta Therapeutics | 2.35 Bn | 1.55 Bn | 251.87 Mn | 952.69 Mn |
| 9 | Vericel | 2.00 Bn | 1.83 Bn | 56.40 Mn | 18.37 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | 24.89 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 24.89 Mn |
| Dec 31, 2025 | 21.96 Mn |
| Jun 30, 2025 | 23.22 Mn |